MX360545B - Método para mejorar el perfil de disolución de un material biológicamente activo. - Google Patents

Método para mejorar el perfil de disolución de un material biológicamente activo.

Info

Publication number
MX360545B
MX360545B MX2011011217A MX2011011217A MX360545B MX 360545 B MX360545 B MX 360545B MX 2011011217 A MX2011011217 A MX 2011011217A MX 2011011217 A MX2011011217 A MX 2011011217A MX 360545 B MX360545 B MX 360545B
Authority
MX
Mexico
Prior art keywords
active material
biologically active
improving
dissolution profile
grinding
Prior art date
Application number
MX2011011217A
Other languages
English (en)
Other versions
MX2011011217A (es
Inventor
Norret Marck
Dodd Aaron
Meiser Felix
Russell Adrian
H Bosch William
Callahan Matt
Original Assignee
Iceutica Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009901741A external-priority patent/AU2009901741A0/en
Application filed by Iceutica Pty Ltd filed Critical Iceutica Pty Ltd
Publication of MX2011011217A publication Critical patent/MX2011011217A/es
Publication of MX360545B publication Critical patent/MX360545B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/12—Powders or granules
    • A01N25/14—Powders or granules wettable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Toxicology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Disintegrating Or Milling (AREA)

Abstract

La presente invención se refiere a un método para mejorar el perfil de disolución de un material biológicamente activo que comprende las etapas de molienda en seco de un material biológicamente activo sólido y una matriz de molienda que se puede moler en un molino que comprende una pluralidad de cuerpos de molienda, por un periodo de tiempo suficiente para producir partículas del material biológicamente activo dispersado en al menos un material de molido parcialmente molido.
MX2011011217A 2009-04-24 2010-04-23 Método para mejorar el perfil de disolución de un material biológicamente activo. MX360545B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17230109P 2009-04-24 2009-04-24
AU2009901741A AU2009901741A0 (en) 2009-04-24 Method for Improving the Dissolution Profile of a Biologically Active Material
PCT/AU2010/000465 WO2010121321A1 (en) 2009-04-24 2010-04-23 Method for improving the dissolution profile of a biologically active material

Publications (2)

Publication Number Publication Date
MX2011011217A MX2011011217A (es) 2012-02-08
MX360545B true MX360545B (es) 2018-10-26

Family

ID=43010604

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011217A MX360545B (es) 2009-04-24 2010-04-23 Método para mejorar el perfil de disolución de un material biológicamente activo.

Country Status (21)

Country Link
US (6) US20120165323A1 (es)
EP (1) EP2421516A4 (es)
JP (3) JP5898613B2 (es)
KR (3) KR101873500B1 (es)
CN (3) CN103830243A (es)
AP (2) AP3629A (es)
AU (2) AU2010239160B2 (es)
BR (1) BRPI1014277A2 (es)
CA (1) CA2759104C (es)
CO (1) CO6470804A2 (es)
EA (1) EA201171280A1 (es)
IL (1) IL215871B (es)
MA (1) MA33293B1 (es)
MX (1) MX360545B (es)
MY (1) MY163538A (es)
NZ (1) NZ595972A (es)
PH (1) PH12015501781A1 (es)
SG (1) SG175308A1 (es)
UA (1) UA110772C2 (es)
WO (1) WO2010121321A1 (es)
ZA (1) ZA201108647B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2653384C (en) 2006-06-30 2017-03-14 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
WO2010121324A1 (en) * 2009-04-24 2010-10-28 Iceutica Pty Ltd A novel formulation of metaxalone
CN102740835A (zh) * 2009-04-24 2012-10-17 伊休蒂卡有限公司 包封的纳米颗粒在工业规模的制备
EA201171279A1 (ru) * 2009-04-24 2012-05-30 Айсьютика Пти Лтд. Производство инкапсулированных наночастиц с высокой объемной долей
SG175315A1 (en) 2009-04-24 2011-11-28 Iceutica Pty Ltd A novel formulation of indomethacin
SG10201401720RA (en) * 2009-04-24 2014-06-27 Iceutica Pty Ltd A novel formulation of naproxen
AU2010239160B2 (en) * 2009-04-24 2014-10-02 Iceutica Pty Ltd Method for improving the dissolution profile of a biologically active material
WO2014152207A1 (en) * 2013-03-15 2014-09-25 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
CN104644556B (zh) * 2013-11-22 2018-05-22 沈阳药科大学 盐酸依福地平固体粉末及其制备方法
AU2015200340B2 (en) * 2014-02-05 2019-01-24 Upl Limited Combinations
US11175268B2 (en) 2014-06-09 2021-11-16 Biometry Inc. Mini point of care gas chromatographic test strip and method to measure analytes
JP6903574B2 (ja) 2014-06-09 2021-07-14 バイオメトリー・インコーポレイテッドＢｉｏｍｅｔｒｙ Ｉｎｃ． 検体を測定するための低コストテストストリップ及び方法
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
HK1252549A1 (zh) * 2015-06-19 2019-05-31 Biotie Therapies, Inc. 控释tozadenant制剂
ES2881435T3 (es) * 2015-10-23 2021-11-29 Basf Se Soluciones sólidas de sustancias odorantes y aromatizantes con polímeros de vinilactama
CN105385739B (zh) * 2015-12-09 2017-09-29 梁尚文 －种从金边蚂蟥中制取蛋白肽的方法
CA3031247A1 (en) 2016-07-19 2018-01-25 Biometry Inc. Methods of and systems for measuring analytes using batch calibratable test strips
CN107853670A (zh) * 2017-10-30 2018-03-30 潍坊友容实业有限公司 一种盐地碱蓬生物盐提取方法
CN108379238B (zh) * 2018-01-17 2020-07-14 南昌大学 一种储存物理稳定性好的环孢素固体脂质纳米粒及其制备方法
CN116327960A (zh) 2018-05-11 2023-06-27 南京清普生物科技有限公司 一种美洛昔康组合物、制剂及其制备方法与应用
KR20210049159A (ko) * 2018-08-31 2021-05-04 케민 인더스트리즈, 인코포레이티드 수분산성 인지질 및 리소인지질을 위한 기술
JP2022504250A (ja) * 2018-10-05 2022-01-13 アンパサンド バイオファーマシューティカルズ インコーポレイテッド ケトンの経皮投与のための製剤および方法
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
CN113133970A (zh) * 2020-01-17 2021-07-20 美国琛蓝营养制品股份有限公司 一种姜黄素复合物及其制备方法和检测方法
EP4171515A1 (en) * 2020-06-25 2023-05-03 Omya International AG Co-ground active(s) comprising product comprising surface-reacted calcium carbonate
TR202017034A2 (tr) * 2020-10-26 2021-09-21 Hacettepe Ueniversitesi Rektoerluek Kuru öğütme yöntemi̇ i̇le hazirlanan ve çözünme hizi arttirilmiş selekoksi̇b i̇çeren farmasöti̇k kompozi̇syonlar
CN114306253B (zh) * 2021-11-16 2023-08-22 扬子江药业集团广州海瑞药业有限公司 格列美脲片剂及其制备方法
JP7745851B2 (ja) * 2021-12-24 2025-09-30 日本乳化剤株式会社 精製イオン液体の製造方法、セルロース溶解液および再生セルロース繊維の製造方法、ならびに繊維組成物および有機繊維コード
CN113996161B (zh) * 2021-12-30 2022-04-19 河北鑫鹏新材料科技有限公司 一种硫转移剂及其制备方法和应用
CN114732009B (zh) * 2022-06-13 2022-08-23 山东百农思达生物科技有限公司 一种含有吡唑醚菌酯和烯酰吗啉的水分散粒剂的制备方法
CN116196273B (zh) * 2023-03-31 2025-04-29 江苏慧聚药业股份有限公司 一种美洛昔康注射液及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
JP4117811B2 (ja) * 1997-04-22 2008-07-16 日本化薬株式会社 フルタミド製剤及びその製法
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US6634576B2 (en) * 2000-08-31 2003-10-21 Rtp Pharma Inc. Milled particles
JP2004099442A (ja) * 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
CN104083342A (zh) * 2004-12-31 2014-10-08 伊休蒂卡有限公司 纳米微粒组合物及其合成方法
JP2009519972A (ja) * 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド 粒子ベースの経肺投与または経鼻投与用製薬の製造方法
US20070178165A1 (en) * 2005-12-15 2007-08-02 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for parenteral administration
CN101568330A (zh) * 2006-06-30 2009-10-28 伊休蒂卡有限公司 用于制备纳米粒形式的生物活性化合物的方法
CA2653384C (en) 2006-06-30 2017-03-14 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
KR20120029398A (ko) * 2009-04-24 2012-03-26 아이슈티카 피티와이 리미티드 디클로페낙의 신규 제형
AU2010239160B2 (en) * 2009-04-24 2014-10-02 Iceutica Pty Ltd Method for improving the dissolution profile of a biologically active material
SG175315A1 (en) * 2009-04-24 2011-11-28 Iceutica Pty Ltd A novel formulation of indomethacin

Also Published As

Publication number Publication date
US20210401753A1 (en) 2021-12-30
WO2010121321A1 (en) 2010-10-28
AP2011005994A0 (en) 2011-12-31
JP2012524717A (ja) 2012-10-18
US20200375903A1 (en) 2020-12-03
CO6470804A2 (es) 2012-06-29
CN102438600A (zh) 2012-05-02
US20130277468A1 (en) 2013-10-24
CN103830243A (zh) 2014-06-04
JP5898613B2 (ja) 2016-04-06
JP2017222643A (ja) 2017-12-21
UA110772C2 (uk) 2016-02-25
KR20160098535A (ko) 2016-08-18
EP2421516A1 (en) 2012-02-29
SG175308A1 (en) 2011-11-28
JP2015199736A (ja) 2015-11-12
BRPI1014277A2 (pt) 2016-10-18
CA2759104A1 (en) 2010-10-28
JP6619386B2 (ja) 2019-12-11
EP2421516A4 (en) 2012-11-07
IL215871B (en) 2019-07-31
AU2010239160B2 (en) 2014-10-02
KR101873500B1 (ko) 2018-08-02
US20120165323A1 (en) 2012-06-28
AU2010239160A1 (en) 2011-11-10
MA33293B1 (fr) 2012-05-02
MY163538A (en) 2017-09-15
IL215871A0 (en) 2012-01-31
NZ595972A (en) 2014-01-31
US20250049720A1 (en) 2025-02-13
EA201171280A1 (ru) 2012-09-28
AU2015243003A1 (en) 2017-05-04
US20180169018A1 (en) 2018-06-21
AP2015008965A0 (en) 2016-01-31
KR20120047207A (ko) 2012-05-11
PH12015501781A1 (en) 2016-10-03
AP3629A (en) 2016-03-08
MX2011011217A (es) 2012-02-08
KR101679522B1 (ko) 2016-11-24
CN104825396A (zh) 2015-08-12
KR20150013948A (ko) 2015-02-05
ZA201108647B (en) 2013-01-30
CA2759104C (en) 2019-01-29

Similar Documents

Publication Publication Date Title
CO6470804A2 (es) Método para mejorar el perfil de disolución de un material biológicamente activo
CL2012000118A1 (es) Articulo adaptado para su uso como una porcion de una superficie de trabajo resistente al desgaste de un rodillo que comprende un compuesto de matriz metálica con particulas inorganicas dispersadas; metodo para fabricarlo; rodillo de molienda; y metodo de fabricación del rodillo.
CO6470810A2 (es) Una formulación novedosa de diclofenaco
DK2637790T3 (da) Fremgangsmåde til formaling af formalingsmateriale og valsemølle
CO6470811A2 (es) Produccion de nanopartículas encapsuladas a escala comercial
CO6470805A2 (es) Producción de monopartículas encapsuladas en fracciones de alto volumen
CL2014002799A1 (es) Rodillo de molienda para la trituración de materiales comprende un cuerpo de rodillo, una ranura lateral formada en cada extremo del cuerpo, un anillo de borde dentro de cada ranura lateral que incluye cavidades de recepción, y una pluralidad de elementos de desgaste recibidos en dichas cavidades; conjunto de molienda.
IT1402783B1 (it) Metodo e impianto di deumidificazione di materiale in forma granulare.
PE20141153A1 (es) Elemento de trituracion y metodo para hacer el mismo
CO6470806A2 (es) Una formulación novedosa de naproxeno
BR112015000582A2 (pt) método, e composição
CO6470807A2 (es) Una formulacion novedosa de indometacina
AR085371A1 (es) Rodillo de trituracion y metodo para fabricarlo
CA143346S (en) Bed frame
CO6470803A2 (es) Una formulacion novedosa de meloxicam
DK2445638T3 (da) Transportabel valsemølle og transportabelt formalingsanlæg
BRPI0816649A2 (pt) moinho de rolos multisseccional e método para reduzir o tamanho de material particulado
ATE551123T1 (de) Mühle und mahlverfahren
EP3714981C0 (de) Aufbereitungsanlage, insbesondere brechanlage, insbesondere gesteinsbrecher
BRPI1009903A2 (pt) conjunto hidráulico para moinhos trituradores
PE20131168A1 (es) Molino triturador con transmisor de par
PL2753182T3 (pl) Środki czynne przeciw szczepom Pseudomonas powodującym choroby gnilne w uprawach grzybów, ich zastosowanie i zawierające je kompozycje
BRPI1004938A2 (pt) triturador de cilindros
FI9719U1 (fi) Mineraalimateriaalin prosessointilaitos
FI20145021A7 (fi) Murskain, mineraalimateriaalin murskauslaitos ja menetelmä painelaakerin käsittelemiseksi murskaimessa

Legal Events

Date Code Title Description
FG Grant or registration